• CX-5461 Induces DNA Damage and Mitotic Catastrophe in Cervic

  2026-04-21

  This study demonstrates that CX-5461, a selective RNA polymerase I inhibitor, impairs cervical cancer cell growth by inducing DNA damage and mitotic catastrophe, and enhances cisplatin sensitivity. The findings provide a mechanistic rationale for targeting Pol I-driven ribosome biogenesis as a therapeutic strategy in both primary and platinum-resistant cervical cancer.

• Modeling HSV-1 Latency in Human iPSC-Derived Sensory Neurons

  2026-04-20

  This study presents a scalable protocol for differentiating human inducible pluripotent stem cells (hiPSCs) into functional sensory neurons, which support latent infection and reactivation of herpes simplex virus 1 (HSV-1). By validating latency-associated viral gene expression and chromatin changes, this system advances mechanistic investigations of HSV-1 in human neuronal contexts, overcoming translational limitations of animal models.

• Translational Immunodetection: Amplifying Impact with HyperF

  2026-04-20

  Explore how the HyperFluor™ 488 Goat Anti-Human IgG (H+L) Antibody integrates advanced fluorescence detection with strategic assay enhancement, empowering translational researchers to achieve exceptional sensitivity and reliability across immunofluorescence, Western blotting, and flow cytometry. Drawing from mechanistic insights, peer-reviewed vaccine research, and protocol benchmarks, this thought-leadership article from APExBIO bridges the gap between technical rigor and translational impact—moving beyond standard product narratives to provide actionable guidance for the next generation of immunodetection.

• PCI-32765 (Ibrutinib): Workflow Optimization in B-Cell and G

  2026-04-19

  PCI-32765 (Ibrutinib) transforms B-cell and ATRX-deficient glioma research with its potent, selective BTK inhibition and robust support for cell viability, signaling, and combinatorial assay designs. This guide delivers actionable, evidence-backed workflows, troubleshooting strategies, and cross-model protocol enhancements, enabling researchers to maximize reproducibility and experimental insight with APExBIO’s gold-standard inhibitor.

• Redefining mRNA Delivery: Translational Impact of ARCA Cy3 E

  2026-04-18

  This thought-leadership article explores the mechanistic innovations and strategic pathways underpinning modern mRNA delivery and visualization, focusing on ARCA Cy3 EGFP mRNA (5-moUTP) from APExBIO. Integrating peer-reviewed advances in lipid nanoparticle engineering and nucleoside modification, it offers translational researchers actionable guidance and a vision for the future of direct-detection, immune-evasive mRNA workflows in mammalian systems.

• Improving In Vitro Evaluation of Cancer Drug Responses

  2026-04-17

  This dissertation by Hannah R. Schwartz introduces refined in vitro methodologies to distinguish between drug-induced growth inhibition and cell death in cancer research. The study reveals that most anticancer drugs influence both proliferation and cell viability, but with distinct timing and magnitude, providing a nuanced framework for interpreting drug efficacy.

• Quizartinib (AC220): Precision Disruption of FLT3 in AML Res

  2026-04-16

  Discover how Quizartinib (AC220) enables mechanistic interrogation and translational advancement in acute myeloid leukemia (AML) research. This article integrates the latest mechanistic data, experimental strategies, and clinical perspectives, providing translational researchers with actionable guidance for leveraging FLT3 inhibition to drive innovation beyond conventional approaches.

• Cycloheximide: Protein Biosynthesis Inhibitor in Apoptosis &

  2026-04-15

  Cycloheximide enables precision manipulation of protein synthesis, empowering apoptosis assays and disease modeling with unprecedented temporal control. Discover how APExBIO’s high-purity Cycloheximide streamlines experimental workflows, optimizes troubleshooting, and delivers reproducible results for advanced translational research.

• HATU-Driven Peptide Synthesis: Strategy, Mechanism, and Impa

  2026-04-14

  This thought-leadership article explores how HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) empowers translational researchers to overcome longstanding bottlenecks in precision peptide synthesis. By weaving together mechanistic insights, competitive benchmarking, and recent breakthroughs—most notably the synthesis of nanomolar IRAP inhibitors—this guide provides actionable strategies that advance both the science and impact of amide bond formation. Featuring expert protocol parameters, evidence-labeled claims, and a rigorous examination of clinical and workflow relevance, the article positions HATU (as supplied by APExBIO) as a cornerstone of next-generation peptide chemistry.

• Fluo-4 AM: Advancing Fluorescent Calcium Indicator Assays

  2026-04-13

  Fluo-4 AM empowers real-time, high-sensitivity intracellular calcium measurement with superior fluorescence intensity and rapid cellular uptake. Its workflow-optimized properties support both foundational cell signaling research and next-generation bioelectronic device development.

• Pregnenolone Carbonitrile: Beyond Hepatic PXR—Neuroprotectio

  2026-04-13

  Explore how Pregnenolone Carbonitrile (PCN) revolutionizes xenobiotic metabolism research by bridging hepatic induction and hippocampal neuroprotection. This article uniquely uncovers PCN’s PXR-independent, glucocorticoid receptor-mediated actions, advancing practical assay design.

• Translational Excellence: FITC Goat Anti-Rabbit IgG (H+L) in

  2026-04-12

  Explore how the FITC Goat Anti-Rabbit IgG (H+L) Antibody empowers sensitive biomarker detection in translational studies, with mechanistic insight and strategic guidance for researchers pursuing early diagnostics, exemplified in diabetic nephropathy proteomics.

• Nonconventional GLP-1 and Glucagon Receptor Interplay Unveil

  2026-04-12

  This study demonstrates that glucagon can act as an unconventional agonist at the GLP-1 receptor, challenging the specificity paradigm of class B GPCRs. Using high-throughput FRET assays for cAMP in engineered cell models, the authors reveal receptor cross-reactivity and provide new frameworks for interpreting metabolic regulation studies.

• ABT-737: Optimizing BCL-2 Protein Inhibition in Cancer Model

  2026-04-11

  ABT-737, a potent BCL-2 protein inhibitor from APExBIO, delivers selective apoptosis induction across aggressive cancer models, outperforming traditional therapies in both specificity and reproducibility. This guide details advanced workflows, troubleshooting strategies, and data-backed protocol enhancements for translational cancer research.

• 0.4% Trypan Blue Solution: Reliable Cell Viability Assessmen

  2026-04-11

  0.4% Trypan Blue Solution provides a practical, validated approach for distinguishing live from dead cells during cell viability measurement and counting. It is optimized for routine use in cytotoxicity and apoptosis assays, but should not be used for diagnostic or clinical applications. Use is limited to research workflows where azo dye-based exclusion is appropriate.

11472 records 1/765 page Next 12345 下5页 Last page